Molecular docking-based screening for novel inhibitors of the human immunodeficiency virus type 1 protease that effectively reduce the viral replication in human cells
Mavian, C. N.; Coman, R. M.; Zhang, X.; Pomeroy, S.; Dunn, B. M.; Sleasman, J. W.; Goodenow, M. M.
Show abstract
Therapeutic pressure by protease inhibitors (PIs) contributes to accumulation of mutations in the HIV type 1 (HIV-1) protease (PR) leading to development of drug resistance with subsequent therapy failure. Current PIs target the active site of PR in a competitive manner. Identification of molecules that exploit non-active site mechanisms of inhibition is essential to overcome resistance to current PIs. Potential non-active site HIV-1 protease (PR) inhibitors (PI) were identified by in silico screening of almost 140,000 molecules targeting the hinge region of PR. Inhibitory activity of best docking compounds was tested in an in vitro PR inhibition biochemical assay. Five compounds inhibited PR from multiple HIV-1 subtypes in vitro and reduced replicative capacity by PI-sensitive or multi-PI resistant HIV-1 variants in human cells ex vivo. Antiviral activity was boosted when combined with Ritonavir, potentially diminishing development of drug resistance, while providing effective treatment for drug resistant HIV-1 variants.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Metal Coordinating Inhibitors of Rift Valley Fever virus Replication 96%
- Identification of Celastrol as a novel HIV-1 Latency Reversal Agent by an Image-Based Screen 95%
- Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants 94%
Similar papers in this journal
- Replication of Equine arteritis virus is efficiently suppressed by purine and pyrimidine biosynthesis inhibitors 95%
- In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication 94%
- Methylene Blue has a potent antiviral activity against SARS-CoV-2 in the absence of UV-activation in vitro 93%
Similar papers in this journal
- Identification of novel Ebola virus inhibitors using biologically contained virus 95%
- Screening and Identification of Lassa Virus Endonuclease-targeting Inhibitors from a Fragment-based Drug Development Library 95%
- Combined in silico docking and in vitro antiviral testing for drug repurposing identified lurasidone and elbasvir as SARS-CoV-2 and HCoV-OC43 inhibitors 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.